Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Failure rates in the hepatocellular carcinoma surveillance process.

Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA.

Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30. doi: 10.1158/1940-6207.CAPR-12-0046. Epub 2012 Jul 30.

2.

Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.

Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ.

Dig Dis Sci. 2017 Aug;62(8):2174-2181. doi: 10.1007/s10620-017-4595-x. Epub 2017 May 4.

PMID:
28474143
3.

Screening process failures for hepatocellular carcinoma.

Singal AG, Marrero JA, Yopp A.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):375-82.

4.

Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.

Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):791-8.e1. doi: 10.1016/j.cgh.2014.06.031. Epub 2014 Jul 11.

5.

Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.

Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A.

Am J Med. 2015 Jan;128(1):90.e1-7. doi: 10.1016/j.amjmed.2014.07.027. Epub 2014 Aug 10.

6.

Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.

Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, Singal AG.

Hepatology. 2017 Mar;65(3):875-884. doi: 10.1002/hep.28770. Epub 2016 Oct 1.

7.

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB.

Hepatology. 2010 Jul;52(1):132-41. doi: 10.1002/hep.23615.

8.

Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers.

McGowan CE, Edwards TP, Luong MU, Hayashi PH.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056. Epub 2014 Aug 10.

9.

Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance.

Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD.

J Clin Gastroenterol. 2016 Mar;50(3):258-65. doi: 10.1097/MCG.0000000000000411.

PMID:
26352107
10.

Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Singal AG, Pillai A, Tiro J.

PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014 Apr.

11.

Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center.

Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, Muir AJ.

Dig Dis Sci. 2010 Dec;55(12):3591-6. doi: 10.1007/s10620-010-1366-3. Epub 2010 Aug 4.

12.

Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.

Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1927-33.e2. doi: 10.1016/j.cgh.2014.02.025. Epub 2014 Feb 26.

PMID:
24582947
13.

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M.

Gut. 2001 Feb;48(2):251-9.

14.

Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study.

Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E.

Cancer Epidemiol. 2014 Dec;38(6):741-7.

PMID:
25454262
15.

Hepatocellular Carcinoma Surveillance: Are We Utilizing It?

Selvapatt N, House H, Brown A.

J Clin Gastroenterol. 2016 Jan;50(1):e8-e12. doi: 10.1097/MCG.0000000000000344.

PMID:
26018132
16.

Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.

van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, Jansen PL, IJzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA.

Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9. doi: 10.1097/MEG.0000000000000527.

PMID:
26629867
17.

Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.

Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, Leon-Rodriguez E.

Cancer. 2006 Oct 15;107(8):1852-8.

18.

Efficacy of a surveillance program for early detection of hepatocellular carcinoma.

Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E.

Cancer. 1996 Sep 1;78(5):977-85.

19.

Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development.

Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A.

Gut. 2001 Jan;48(1):110-5.

20.

Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis.

Aberra FB, Essenmacher M, Fisher N, Volk ML.

Dig Dis Sci. 2013 Apr;58(4):1157-60. doi: 10.1007/s10620-012-2461-4. Epub 2012 Nov 1.

PMID:
23111632

Supplemental Content

Support Center